RxDoctor Payments Data

Venkata Pante, MD

Internal Medicine · Saint Louis, MONPI 1356314298

Payments from drug & device makers

$1,664in general payments, 2019–2025

Across 101 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$406
  • Johnson & Johnson$281
  • Novartis$172
  • AstraZeneca$143
  • Amgen$96
  • E.r. Squibb & Sons, L.L.C.$91
  • plus $476 from 16 others

What the payments were for

  • Food & beverage$1,664100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,664 in reported general payments places this provider in the 75th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$106,849
Medicare patients
297
Services billed
1,141

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban68$69,092
JanuviaSitagliptin Phosphate43$43,970
TrulicityDulaglutide26$40,934
JardianceEmpagliflozin22$36,997
EntrestoSacubitril/Valsartan13$27,159
OzempicSemaglutide25$26,359
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$17,401
FarxigaDapagliflozin Propanediol15$16,726
MyrbetriqMirabegron18$15,683
Tresiba Flextouch U-100Insulin Degludec22$10,263
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$4,683
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen120$3,269
ArexvyRsvpref3 Antigen/As01e/Pf14$3,209
Atorvastatin Calcium297$2,412
Albuterol Sulfate HfaAlbuterol Sulfate90$2,323

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$70$43,97043 claims
Boehringer IngelheimJardiance$16$36,99722 claims
NovartisEntresto$172$27,15913 claims
Novo NordiskOzempic$87$26,35925 claims
GSKTrelegy Ellipta, Arexvy$54$20,61032 claims
AstraZenecaFarxiga$143$16,72615 claims
AbbVieSynthroid$406$1,22618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →